http://www.hardmanandco.com/Research/Alliance_June2005.pdf


Web Site : http://www.alliancepharma.co.uk

http://www.hemscott.com/hstoday/Focus_2005/Alliance%20Pharma_1205_2005.htm

Hardmans late June 2005 update

Fair value at 30p

http://www.hardmanandco.com/Research/Alliance_June2005.pdf

squidd also new presentation on June 22nd 2005 to G.C.I. is available;

http://miranda.hemscott.com/ir/aph/pdf/2005_06_22_growth_company_investor.pdf

what do you think ?

PpP: As a holder of 50k shares in APH, I enjoyed reading the 2 reports. But as a layman, I cannot really comment on the potential of the new products and those under development, other than to agree in general terms about growth prospects.
In any case, I've read too many glowing analysts reports to place to much reliance on them, because at the end of the day, so much depends upon the energy and enterprise of the management team. With APH, I think they know what they are at and are making the right moves, so I'm happy to be on board
(in contrast to ELA, who I felt voiced some muddled thinking at their recent AGM).
But the reports are very positive and help confirm my own views. Additionally, the chart looks to me like a classic recovery, so I'll be looking for an sp of 30p or more by Xmas.
sd.

PpP: I had expected some profit taking here, and it may yet occur, but meanwhile I note what you say about profit taking at VLK. Encouraged by a rise in my TED holding, I will be inclined to add to APH on any dips.
sd.

squidd its very interesting so far that APH remains stable if it can keep this up the next move up will also be quick and strong when it happens. Like you if it drops I will add on the bottom of any drop.

Alliance Pharma PLC
29 July 2005

For Immediate Release 29 July 2005

ALLIANCE PHARMA PLC
('Alliance' or 'the Company')

Leading distributor signed in Turkey for Periostat(R)

Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,
is pleased to announce that it has entered into a distribution agreement with
Vem IIac to register, distribute and market Periostat in Turkey. Simultaneously
to this agreement, Alliance has also extended its agreement with CollaGenex to
add Turkey to its list of available territories.

Periostat is the first and only approved prescription medicine for the treatment of the severe gum disease periodontitis.

Vem IIac, based in Ankara, is a specialist dental pharmaceutical company and is
highly experienced in the dental market in Turkey, where it currently
distributes and sells a range of dental anaesthetics and consumables to more
than 20,000 dental clinics.

Statistics indicate that 22 per cent of the Turkish population has advanced
periodontitis, representing a potential market of approximately nine million
people. Periostat will be the only enzyme suppression product on the market in
Turkey to treat periodontitis.

Alliance and Vem IIac have compiled and submitted the dossier to secure the
marketing authorisation for Periostat in Turkey. This registration process is
expected to take between eighteen months and two years.

Commenting on the news, John Dawson, Alliance Pharma's Chief Executive, said:
'I am extremely delighted with these two agreements. Periostat is a major growth opportunity for Alliance Pharma and this agreement with Vem IIac increases our international reach into a well developed dental market that represents a significant commercial opportunity. It has also produced a good understanding between us and CollaGenex on the way forward to exploit markets that were outside our original agreement.'

For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director

www.alliancepharma.co.uk

PpP: APH my No 2 candidate for top-up and after that news, for which thanks, I'd better get in quickly.
On VLK, yours was a timely posting yesterday, and I think I'll just hopefully enjoy the ride from here.
sd.

squidd yes I have topped up in VLK but I am stuck on which one is the next candidate as they are all at times when news, results or trend will move them higher so will have to sit down and think about this over the weekend.

squidd looking at those two big trades yesterday you might be getting some holdings increase news next week so very nicely timed buy if it is.

PpP: You were right about the new holdings. Have noted that Aviva, via their subsidiary Morley, have joined the stake holders, taking up 10% of APH. I'm glad that us ordinary mortals were able to clamber aboard ahead of the action.
sd.

squidd I knew something was going on then and its good news that comes through,will be adding more in the coming months.

PpP: I slept soundly yesterday morning as ULT climbed 50% until wakened by a call from a day trader friend, who urged me to sell. But after we talked about the various scenarios for the global roll out of ULT's CBT and a possible reaction from beleaguered pharmas, defending their tranquilliser pills, he agreed that I would have to buy back pdq, so I'm still in.
I hope that somewhere along the line people will recognise that APH's Posidorm is also a type of traquilliser, but being the body's own produce, is unlikely to have side effects.
sd.

squidd ULT is still up and down but if they can come up with the goods then it should be a lot more up than down in future.

Very interested in BOI at the moment, been slowely adding and I think this will wake up (no Posiderm for BOI to sleep on) very soon. Could give some strong gains through this year and next.

PpP: I sold my APH earlier in the week, at a healthy profit, in order to top up my front runners CSB, AEX and of course ULT. So, very grateful for your hard work on APH which has helped fill my pockets and hoping you are with us on ULT.
sd.

squidd, yes I have taken a small go with ULT and its moving ups so thanks for the nod on ULT. Am taking a closer look at CSB and AEX.

One of my small holdings GRL went up today on very good news, it might have some more go in it too.

Alliance Pharma PLC
11 October 2005
For Immediate Release 11 October 2005

ALLIANCE PHARMA PLC
('Alliance' or 'the Company')
Notification of Interim Results

On behalf of our client Alliance Pharma plc (AIM: APH), the emerging speciality
pharmaceutical company, we notify that they will be reporting their Interims
Results for the six months ended 31 August, on Thursday 3 November, 2005.

For further information:
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court/Lisa Baderoon/Rebecca Skye Dietrich

Notes to editors
About Alliance Pharma
Alliance Pharma, founded in 1996, is an AIM listed emerging speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a
strong track record of acquiring the rights to established niche brands and
owns, or shares, the rights to 30 branded pharmaceutical products and continues
to explore opportunities to expand the range.
Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to pharmaceutical wholesalers which
service both hospital and retail pharmacies with their prescription
requirements.
Alliance Pharma is also developing novel products for sleep disorders and the
induction of labour.
Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.

Alliance Pharma PLC
03 November 2005

For Immediate Release 3 November 2005

ALLIANCE PHARMA PLC
('Alliance' or 'the Company')

Uniflu UK disposal raises 500,000

Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,
is pleased to announce that it has divested Uniflu, its cold and flu product,
for a one-off payment of 500,000.

Uniflu was acquired as part of the acquisition of Forceval, a prescription based multi-vitamin for clinical malnutrition, in November 2004. The UK business for Uniflu, as a consumer healthcare product, is non-core to Alliance, therefore the company has taken the decision to divest the brand to G R Lane Health Products Ltd based in Gloucester, UK, for a one-off payment of 500,000. Alliance retains its Uniflu export business, with annual sales of 419,000 which is managed via distributors.

Uniflu's presence in the UK market is underdeveloped compared with its position
in several other markets, particularly Lebanon where it is market leader in the
cold and flu segment.

Commenting on the news, John Dawson, Alliance Pharma's Chief Executive, said:

'We have taken the decision to divest Uniflu for a one-off payment as the
product is non-core to the Alliance Pharma business. We continue to retain the
export sales on Uniflu as that market is further developed and offers more value going forward.'

For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Maddy Scott, Finance Director

www.alliancepharma.co.uk

ALLIANCE PHARMA PLC

('Alliance Pharma' or 'the Company')

Interim Results for the six month period ended 31 Augst 2005

Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,
is pleased to announce its interim results for the half year ended 31 August
2005.

Financial Highlights

Sales up 35.5% to 7.5m
Profit after tax, on an IFRS basis was 385K
Gross margin improvement of 53.6%
Operating cashflow remains strong at 1.6m
Basic earnings per share of 0.26p
Financial year changing to December 31st - commencing December 2005

Operational Highlights

Phase III clinical trials on Isprelor(TM), (induction of labour)

- trials expected to complete the middle of 2006

Phase III trials on Posidorm(TM), (melatonin for sleeping disorders),

- on track for introduction in 2007

Selective acquisition of reputable prescription brands under discussion

Commenting on the results, Michael Gatenby, Alliance Pharma's Chairman, said:
'Our interim results for the 6 months to August 2005 represent another period of good, on-target, performance from the current business with solid progress also being made on the development projects. Significant progress has also been made in building and strengthening the managerial team...... We look forward to the next half year with continued optimism.'


Diluted EPS 0.46p

Anyone know why it has fallen 9% today?

Its probably just the December syndrome, end of year, and MM's want to finish the year at evens on as many stocks as they can, so this is why in December on MM controlled stocks, there can be wild price swings up and down as year end positons are cleared and stated.

Alliance Pharma PLC
23 March 2006




FOR IMMEDIATE RELEASE 23 MARCH 2006


ALLIANCE PHARMA PLC
('Alliance Pharma' or 'the Company')

Preliminary Results for the 10 month period ended 31 December 2005

Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,
is pleased to announce its preliminary results for the ten month period ended 31
December 2005. The results cover a 10 month period owing to a change to the
Company's year end to 31 December 2005, bringing the Company's year end into
line with that of its peers.

Financial Highlights



Sales for the 10 month period of 12.28 million (12 months to 31
December 2004: 11.83m)

Sales growth on an annualised basis of 24.6%

Gross margin improvement to 54.3% (2004: 52.4%)

Operating cashflow remains strong at 1.79 million (2004: 1.57m)

Earnings before interest and tax of 2.17 million (2004: 2.26m)

Pre-tax profit of 0.66 million (2004: 0.41m)

Operational Highlights

Launch of Dental Products division and promotion of Periostat for
periodontitis

Launch of International Division for marketing of Periostat and
Forceval

Start of Phase III clinical trials of Posidorm for sleep disorders

Acquisition of Hydromol dermatology range post the year end

Commenting on the results, Michael Gatenby, Alliance Pharma's Chairman, said: '
During the period under review, Alliance has moved closer to its goal of
delivering substantial and growing revenue streams from brands both acquired and
developed in-house. All our efforts will continue to be directed towards
achieving this goal.'